Investment case
IQVIA Holdings Inc.
IQV · 5 developments mapped · last assessed 2026-09-03
Market Ontology has mapped 5 macro, policy, and market developments to IQVIA Holdings Inc. since 2026-09-03. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for IQV yet, so no modelled value is shown. The IQV valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run IQV on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Open question
Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45M
Increased competition in the early-phase clinical research organization (CRO) market, potentially impacting pricing power or market share for established players.
· Moves market share in early phase cro services, pricing power in competitive segments
What changed, by assumption
- 2026-09-03Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45M
- 2026-09-03Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45 Million
- 2026-09-03Fortrea to Acquire Worldwide Clinical Trials Early Phase Division for $45 Million
- 2026-09-03Fortrea to Acquire Worldwide Clinical Trials Early Phase Unit for $45M
- 2026-09-03Fortrea to Acquire Worldwide Clinical Early Phase Unit for $45M
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-06-12 | Cost of capital | Bearish | IG cost of debt is below blended cost of capital; weighting effect lowers WACC. | 0.70 |
| 2026-06-12 | Interest expense | Bullish | New IG coupon adds to recurring interest expense. | 0.70 |
| 2026-06-12 | Net debt | Bullish | Investment-grade issuance adds gross debt to the balance sheet. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-03 | Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45M | watch | 3-12m | 0.30 |
| 2026-09-03 | Fortrea to Acquire Worldwide Clinical Early Phase Unit for $45M | watch | 3-12m | 0.20 |
| 2026-09-03 | Fortrea to Acquire Worldwide Clinical Trials Early Phase Unit for $45M | mixed | 3-12m | 0.20 |
| 2026-09-03 | Fortrea to Acquire Worldwide Clinical Trials Early Phase Division for $45 Million | mixed | 3-12m | 0.30 |
| 2026-09-03 | Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45 Million | mixed | 3-12m | 0.20 |